Canada markets closed

Medicus Pharma Ltd. (MDCX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.0000-0.2000 (-9.09%)
At close: 02:20PM EDT
Full screen
Previous Close2.2000
Open2.0000
Bid1.9500 x N/A
Ask2.0700 x N/A
Day's Range2.0000 - 2.0500
52 Week Range0.3100 - 3.0500
Volume6,500
Avg. Volume1,364
Market Cap32.307M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.90
  • Newsfile

    Medicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes

    Toronto, Ontario--(Newsfile Corp. - May 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed the first closing of its previously announced private placement (the "Private Placement") of 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). The Company issued US$5,172,500 aggregate principal amount of Notes in the first closing, which was unbrokered. The Company may issue additional Notes in one or more further ...

  • Newsfile

    Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes

    Toronto, Ontario--(Newsfile Corp. - April 25, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it intends to complete the first closing of a private placement (the "Private Placement") of its 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). Approximately US$5,172,500 aggregate principal amount of Notes will be issued at the first closing, which is expected to occur on or about May 1st , 2024, ...

  • Newsfile

    Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin

    FDA Agrees with the Study Design of Randomizing Up To 60 Participants with Nodular Type of Basal Cell Carcinoma Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce the receipt of comments from the U.S Food and Drug Administration (FDA).The clinical non-hold comments from the FDA consider the results of the study exploratory and request the Company to provide data from clinical studies ...